EP Patent

EP1485103A1 — Sulfatase inhibiting continuous progestogen contraceptive regimens

Assigned to Janssen Pharmaceutica NV · Expires 2004-12-15 · 21y expired

What this patent protects

A method of contraception is described comprising the step of administering to a menstruating female a cycle of contraceptive therapy, said cycle of therapy including, for at most 35 successive days, the administration of a combination of an estrogen and a progestogen in a contra…

USPTO Abstract

A method of contraception is described comprising the step of administering to a menstruating female a cycle of contraceptive therapy, said cycle of therapy including, for at most 35 successive days, the administration of a combination of an estrogen and a progestogen in a contraceptively effective daily dosage wherein said progestogen is a potent sulfatase inhibiting progestogen and said cycle of therapy including 4-8 days in which said progestogen is administered in the absence of estrogen administration following said at most 35 successive days.

Drugs covered by this patent

Patent Metadata

Patent number
EP1485103A1
Jurisdiction
EP
Classification
Expires
2004-12-15
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.